Neuren Pharmaceuticals Limited (NURPF) Q2 2026 Earnings Call Transcript

SA Transcripts 162.01K Followers Follow Neuren Pharmaceuticals Limited ( NURPF ) Q2 2026 Earnings Call August 25, 2026 9:00 PM EDT Company Participants Gerry Zhao - Chief Business Officer Jonathan Pilcher - CEO, MD & Executive Director Presentation Gerry Zhao Chief Business Officer Good morning, and welcome to today's investor webinar to discuss Neuren's First Half 2026 Financial Results and the company's first ever dividend program. My name is Gerry Zhao, Chief Business Officer at Neuren. Joining me today are our Chairman, Patrick Davies; and Chief Executive Officer, Jon Pilcher. Jon will make the presentation followed by a Q&A session. A copy of today's presentation has been released to the ASX and is also available on our website. [Operator Instructions] Before proceeding, please note that today's webinar will include forward-looking statements, which are subject to risks and uncertainties that may lead to different outcomes. I'll now hand over to Jon to commence the presentation. Jonathan Pilcher CEO, MD & Executive Director Thanks very much, Gerry. Good morning, everyone. Thank you for sparing your time to listen to us this morning. We are going to try and keep this to 40 minutes, if we can. We've had some pre-submitted questions, many of which I'll address during the slides that I go through, and then we'll come to the other questions. But apologies in advance if we don't get to your questions as we are going to stop after 40 minutes. So, I want to start with this slide, which we've used for a while. And this is my mantra to investors that I strongly believe you can get the best of both worlds with Neuren. So, you have $287 million of cash -- the cash generation, strong generation from DAYBUE. And that picture has just got stronger again with the approval yesterday in Europe, which I'll come to in a minute. So, you have all of that.